|Individual probes for monitoring (FISH Test)|
The management of hematologic malignancies has led the way in establishing the use of regular laboratory testing to assess for residual disease on an ongoing basis. The goals of minimal residual disease (MRD) monitoring for leukemias include (1) demonstration of the effectiveness of initial therapy; (2) monitoring for treatment resistance or relapse; and (3) dissecting the mechanisms of treatment failure to help in selection of alternative therapies. Monitoring is based on alteratios which were detected in the first test, by individual probes.
|Գին՝ 25 000 AMD|